SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Bayer Aktiengesellschaft, et al. – ‘SC 13D/A’ on 11/20/12 re: Schiff Nutrition International, Inc. – EX-5

On:  Tuesday, 11/20/12, at 6:14am ET   ·   Accession #:  1193125-12-476389   ·   File #:  5-51083

Previous ‘SC 13D’:  ‘SC 13D’ on 11/7/12   ·   Next & Latest:  ‘SC 13D/A’ on 11/26/12

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

11/20/12  Bayer Aktiengesellschaft          SC 13D/A               2:145K Schiff Nutrition Int’l, Inc.      RR Donnelley/FA
          Bayer AG
          Bayer Corp
          Bayer Healthcare LLC
          Willow Road Co

Amendment to General Statement of Beneficial Ownership   —   Schedule 13D
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: SC 13D/A    Amendment No.1 to Schedule 13-D                     HTML     70K 
 2: EX-5        Opinion re: Legality                                HTML     15K 


EX-5   —   Opinion re: Legality


This exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



  LETTER  

Exhibit 5

 

LOGO

VIA FACSIMILE

Schiff Nutrition International, Inc.

2002 South 5070 West

Salt Lake City, UT 84104-4726

Attention:         General Counsel

Facsimile No.: (801) 975-1924

 

Re: Agreement and Plan of Merger

Dear Mr. Milsten:

 

Reference is made to: (i) that certain Agreement and Plan of Merger, dated as of October 29, 2012 (the “Merger Agreement”), by and among Bayer HealthCare LLC, a Delaware limited liability company (“Parent”), Willow Road Company, a Delaware corporation and a wholly-owned Subsidiary of Parent (“Merger Sub”), and Schiff Nutrition International, Inc., a Delaware corporation (the “Company”); and (ii) your letter to Dr. Jan Heinemann dated November 18, 2012 (the “November 18 Letter”), which gave notice with respect to the $42.00 per common share, all cash Acquisition Proposal from Reckitt Benckiser Group plc dated November 15, 2012 (the “November 18 Proposal”). All capitalized terms used but not otherwise defined herein shall have the definitions set forth in the Merger Agreement.   

 

19 November 2012

Bayer AG’s Board of Management has decided not to propose any increase to the Merger Consideration payable in respect of the Company Common Stock in response to the November 18 Proposal. Bayer AG’s Board of Management continues to believe that the Merger transaction would represent a logical and strategic addition for Bayer’s Consumer Care business. However, it came to the conclusion that entering a competitive bidding process in response to the November 18 Proposal would result in a price outside Bayer’s set financial criteria. Having completed a number of successful acquisitions, Bayer plans to continue its strategy to augment organic growth with strategic bolt-on acquisitions.   
Parent and Merger Sub hereby waive the conditions set forth in clauses i. and ii. of the second proviso of the first sentence of Section 5.3(f) of the Merger Agreement (the “Waived Conditions”) solely with respect to the November 18 Proposal. This waiver applies solely to the Waived Conditions, so that the actions specified in clauses (y) and (z) of such proviso (the “Actions”) may not be taken with respect to the November 18 Proposal unless the Company complies with the other provisions of Section 5.3(f), including the first proviso to such sentence, clause iii. of the second proviso to such sentence, and the sentences following clause iii, as well as any other provision of the Agreement that would be   


applicable to the Actions. This waiver does not and shall not apply to any Acquisition Proposal other than the November 18 Proposal or any actions taken with respect thereto, and in the event of any material revisions to the financial or other material terms of the November 18 Proposal, the applicable provisions of Section 5.3(f) of the Merger Agreement shall continue to apply. This waiver does not and shall not apply to any failure to comply with any provision of the Merger Agreement other than the Waived Conditions, and Parent and Merger Sub reserve all rights with respect to any such failure.   

[Signature page follows]

 

2


Very truly yours,
BAYER HEALTHCARE LLC
By:  

/s/ William B. Dodero

  Name:   William B. Dodero
  Title:   Assistant Secretary
WILLOW ROAD COMPANY
By:  

/s/ William B. Dodero

  Name:   William B. Dodero
  Title:   Secretary


CC: Sullivan & Cromwell LLP

125 Broad Street

New York, NY 10004

Attention:       Matthew G. Hurd

Facsimile No.: (212) 558-3588

Latham & Watkins LLP

140 Scott Drive

Menlo Park, California 94062

Attention:        Tad Freese

                         Jamie Leigh

Facsimile No.: (650) 463-2600

Schiff Nutrition International, Inc.

2101 Park Avenue, Suite 101

Emeryville, CA 94608

Attention:        General Counsel

Facsimile No.: (510) 922-1271


Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘SC 13D/A’ Filing    Date    Other Filings
Filed on:11/20/128-K
11/18/12
11/15/12SC TO-C
10/29/12
 List all Filings 
Top
Filing Submission 0001193125-12-476389   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Sat., Apr. 27, 5:26:00.1pm ET